NEW YORK (GenomeWeb News) – Med BioGene today reported a second quarter net loss of C$139,171 (US$132,159), up slightly from a net loss of C$102,121 for the second quarter of 2012.

The Vancouver, British Columbia-based molecular diagnostics developer didn't report any revenues for the quarter. It noted that its commercialization partner, Precision Therapeutics, recently completed the final clinical studies on the firm's GeneFx Lung test and expects to launch the assay in the US as a CLIA waived test this fall.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.